Researchers at Georgia State University have developed a bispecific nanobody that neutralizes SARS-CoV, SARS-CoV-2, and MERS-CoV, according to a study published in the journal ACS Nano. This therapeutic antibody demonstrates the potential to treat infections caused by these highly pathogenic human coronaviruses.
The study’s findings highlight a significant gap in existing treatments for these viruses, which continue to pose risks for human health and potential outbreaks. The team, led by researchers from the Institute for Biomedical Sciences at Georgia State University, collaborated with other U.S. universities and institutions to explore a broad-spectrum therapeutic solution.
Nanobodies, which are small antibody fragments also known as single-domain antibodies, are notably smaller than traditional antibodies and are capable of binding strongly to specific viral proteins. The researchers identified nanobodies from immunized phage display libraries that effectively attached to the receptor-binding domains (RBDs) of SARS-CoV, SARS-CoV-2, and MERS-CoV. One specific nanobody, referred to as 3B11, was shown to neutralize various strains of both SARS-CoV and SARS-CoV-2, while another, 1C11, effectively neutralized all strains of MERS-CoV tested.
The mechanism behind this effectiveness lies in the blockade of viral RBD interaction with human cell receptors. The researchers utilized advanced techniques, including cryo-electron microscopy and computational modeling, to reveal the precise viral protein sites that the nanobodies target. This understanding aids in explaining their strong antiviral capabilities.
Following these developments, the team engineered a bispecific nanobody known as 3B11−1C11-Fc, which binds to all three RBDs. This bispecific nanobody demonstrated stability under various pH and temperature conditions and was produced in high yields in mammalian cells, indicating potential for large-scale manufacturing. In mouse models, a single administration of this agent significantly reduced viral loads and prevented infections from SARS-CoV, SARS-CoV-2, and MERS-CoV without severe clinical symptoms observed in most cases.
“Our goal was to develop a single therapeutic that could address all three highly pathogenic coronaviruses,” said Lanying Du, a Distinguished University Professor at Georgia State and a corresponding author of the study. She highlighted the nanobody’s effectiveness in neutralizing the three coronaviruses as a promising step towards further therapeutic development.
The research represents a significant advancement in the search for efficient treatments against coronaviruses, addressing a pressing global health challenge. Future studies may focus on additional testing and the potential for clinical applications of this bispecific nanobody.


